HPIC Share Price | Hayat Pharmaceutical Industries Co. Ltd. Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Hayat Pharmaceutical Industries Co. Ltd. with Similar Stocks

Dar Al Dawa Development & Investment Co. Ltd.Philadelphia Pharmaceuticals Co.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Flat results in Dec 25

DIVIDEND PAYOUT RATIO(Y) Lowest at 0%
ROCE(HY) Lowest at 0%
RAW MATERIAL COST(Y) Grown by 6.98% (YoY)

With ROE of 0.00%, it has a expensive valuation with a 0.00 Price to Book Value

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

JOD Million (Small Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.20

Return on Equity

7.18%

Price to Book

0.00

Revenue and Profits:

Net Sales:

5 Million

(Quarterly Results - Dec 2025)

Net Profit:

1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-4.26%

6 Months

0.96%

1 Year

12.5%

2 Years

27.53%

3 Years

-0.94%

4 Years

-2.78%

5 Years

-5.69%

Hayat Pharmaceutical Industries Co. Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.63%

EBIT Growth (5y)

3.45%

EBIT to Interest (avg)

3.30

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.14

Sales to Capital Employed (avg)

0.49

Tax Ratio

12.80%

Dividend Payout Ratio

78.19%

Pledged Shares

Institutional Holding

ROCE (avg)

13.28%

ROE (avg)

10.21%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

EV to EBITDA

EV to Capital Employed

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

ROE (Latest)

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -8.77% vs 67.65% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 80.00% vs 25.00% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.20",
          "val2": "5.70",
          "chgp": "-8.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.10",
          "val2": "1.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.90",
          "val2": "0.50",
          "chgp": "80.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "147.60%",
          "val2": "138.50%",
          "chgp": "0.91%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 2.40% vs 5.70% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -25.81% vs 34.78% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "17.10",
          "val2": "16.70",
          "chgp": "2.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3.70",
          "val2": "4.40",
          "chgp": "-15.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.30",
          "val2": "3.10",
          "chgp": "-25.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "140.30%",
          "val2": "192.10%",
          "chgp": "-5.18%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

5.20

5.70

-8.77%

Operating Profit (PBDIT) excl Other Income

1.10

Interest

0.00

0.10

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

0.90

0.50

80.00%

Operating Profit Margin (Excl OI)

147.60%

138.50%

0.91%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is -8.77% vs 67.65% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 80.00% vs 25.00% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

17.10

16.70

2.40%

Operating Profit (PBDIT) excl Other Income

3.70

4.40

-15.91%

Interest

0.10

0.20

-50.00%

Exceptional Items

0.00

Consolidate Net Profit

2.30

3.10

-25.81%

Operating Profit Margin (Excl OI)

140.30%

192.10%

-5.18%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 2.40% vs 5.70% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -25.81% vs 34.78% in Dec 2024

All Annual Results

Company CV

About Hayat Pharmaceutical Industries Co. Ltd.

Hayat Pharmaceutical Industries Co. Ltd.

Pharmaceuticals & Biotechnology

Hayat Pharmaceutical Industries Company PSC is a Jordan-based company engaged in the pharmaceutical sector. The Company specializes in the manufacture of different forms of human pharmaceuticals, veterinary medicines, medical plasters, medical gauze and medical braces, in addition to the production of skin care and beauty supplies and surgical suture. The Company’s manufacturing facility is spread over an approximately 8,000 square meter area on the outskirts of the capital city Amman. The Company’s production areas are divided into the following: Solid production area, which covers tablets, capsules, dry suspension, suppositories, syrups and solutions, cream and ointments, and Semi-solid and Liquid production area, which includes creams, ointments, gels and emulsions, suppositories line, syrups line and shampoo line. The Company’s products include Anti-microbials, Gynecological, Dermatological, Gastrointestinal, Antihypertensives and Vasoactive, Neurological, and Respiratory products.

Company Coordinates

Company Details

Nile St. Al-Rajeeb,, P.O.Box 1564 AMMAN None : 11118

Tel: 962 6 4162607

http://www.hayatpharma.com

Registrar Details